Showing results (341-350 of 427) with videos related to
Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342Eric P Winer, Donald A Berry, Susan Woolf, et al.Science Translational Medicine|August 21, 2015
Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesisBo Ri Seo, Priya Bhardwaj, Siyoung Choi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Allison M Deal, Mark G Kris, et al.JAMA Oncology|November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast CancerChau Dang, Hao Guo, Julie Najita, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2008
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialEdith A Perez, Vera J Suman, Nancy E Davidson, et al.Cancer Prevention Research (Philadelphia, Pa.)|July 26, 2012
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancerKatherine D Crew, Powel Brown, Heather Greenlee, et al.Analytical Chemistry|January 12, 2016
Noninvasive Detection of Inflammatory Changes in White Adipose Tissue by Label-Free Raman SpectroscopyAbigail S Haka, Erika Sue, Chi Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)William M Sikov, Donald A Berry, Charles M Perou, et al.Clinical Breast Cancer|August 24, 2017
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast CancerJosé Baselga, Claudio Zamagni, Patricia Gómez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901Vanessa B Sheppard, Leigh Anne Faul, George Luta, et al.Pageof 43